Literature DB >> 28248445

Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study).

A Aguilera1, D Navarro1, F Rodríguez-Frias2, I Viciana3, A M Martínez-Sapiña4, M J Rodríguez5, E Martró6, M C Lozano7, E Coletta8, L Cardeñoso9, A Suárez10, M Trigo11, J Rodríguez-Granjer12, N Montiel13, A de la Iglesia14, J C Alados15, C Vegas16, S Bernal17, F Fernández-Cuenca18, M J Pena19, G Reina20, S García-Bujalance21, M J Echevarria22, L Benítez23, S Pérez-Castro24, D Ocete25, I García-Arata26, C Guerrero27, M Rodríguez-Iglesias28, P Casas29, F García29.   

Abstract

We report the largest study on the prevalence and distribution of HCV genotypes in Spain (2000-2015), and we relate them with clinical, epidemiological and virological factors. Patients from 29 hospitals in 10 autonomous communities (Andalusia, Aragon, Castilla-Leon, Catalonia, Galicia, Canary Islands, Madrid Community, Valencian Community, Murcia Region and Basque Country) have been studied. Annual distribution of HCV genotypes and subtypes, as well as gender, age, transmission route, HIV and/or HBV coinfection, and treatment details were recorded. We included 48595 chronically HCV-infected patients with the following characteristics: median age 51 years (IQR, 44-58), 67.9% male, 19.1% HIV-coinfected, 23.5% HBV-coinfected. Parenteral transmission route was the most frequent (58.7%). Genotype distribution was 66.9% GT1 (24.9% subtype 1a and 37.9% subtype 1b), 2.8% GT2, 17.3% GT3, 11.4% GT4 and 0.1% GT5 and 0.02% GT6. LiPA was the most widely HCV genotyping test used (52.4%). HCV subtype 1a and genotypes 3 and 4 were closely associated with male gender, parenteral route of infection and HIV and HBV coinfection; in contrast, subtype 1b and genotype 2 were associated with female gender, nonparenteral route and mono-infection. Age was related to genotype distribution, and different patterns of distribution and biodiversity index were observed between different geographical areas. Finally, we describe how treatment and changes in transmission routes may have affected HCV genotype prevalence and distribution patterns. We present the most recent data on molecular epidemiology of hepatitis C virus in Spain. This study confirms that genotype distributions vary with age, sex, HIV and HBV coinfection and within geographical areas and epidemiological groups.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  epidemiological/geographical distribution; genotype; hepatitis C virus; prevalence

Mesh:

Year:  2017        PMID: 28248445     DOI: 10.1111/jvh.12700

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  10 in total

1.  Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data.

Authors:  Alev Çetin Duran; Özgül Kaya Çetinkaya; Ayça Arzu Sayıner; Gülşah Şeydaoğlu; Emre Özkarataş; Hakan Abacıoğlu
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

2.  Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain.

Authors:  Ana Belen Pérez; Bram Vrancken; Natalia Chueca; Antonio Aguilera; Gabriel Reina; Miguel García-Del Toro; Francisco Vera; Miguel Angel Von Wichman; Juan Ignacio Arenas; Francisco Téllez; Juan A Pineda; Mohamed Omar; Enrique Bernal; Antonio Rivero-Juárez; Elisa Fernández-Fuertes; Alberto de la Iglesia; Juan Manuel Pascasio; Philippe Lemey; Féderico Garcia; Lize Cuypers
Journal:  Euro Surveill       Date:  2019-02

3.  Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay.

Authors:  V Saludes; A Antuori; B Reinhardt; I Viciana; E Clavijo; L Schreiber; M Tenenbaum; F Rodriguez-Frias; J Quer; L Matas; E Martró
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

4.  Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.

Authors:  Arnolfo Petruzziello; Rocco Sabatino; Giovanna Loquercio; Annunziata Guzzo; Lucia Di Capua; Francesco Labonia; Anna Cozzolino; Rosa Azzaro; Gerardo Botti
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

5.  Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study.

Authors:  T Semenova; B Nemoz; V Thibault; G Lagathu; G Duverlie; E Brochot; P Trimoulet; C Payan; S Vallet; C Henquell; S Chevaliez; M Bouvier-Alias; S Maylin; A-M Roque-Afonso; L Izquierdo; F Lunel-Fabiani; P Marcellin; P Morand; V Leroy; S Larrat
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

6.  Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.

Authors:  Ana Belén Pérez; Natalia Chueca; Juan Macías; Juan Antonio Pineda; Javier Salmerón; Antonio Rivero-Juárez; Carmen Hidalgo-Tenorio; María Dolores Espinosa; Francisco Téllez; Miguel Ángel Von-Wichmann; Mohamed Omar; Jesús Santos; José Hernández-Quero; José Joaquin Antón; Antonio Collado; Ana Belén Lozano; Miguel García-Deltoro; Marta Casado; Juan Manuel Pascasio; Aida Selfa; José Miguel Rosales; Alberto De la Iglesia; Juan Ignacio Arenas; Silvia García-Bujalance; María José Ríos; Enrique Bernal; Onofre Martínez; Antonio García-Herola; Mónica Vélez; Pilar Rincón; Federico García
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.752

7.  5' UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt.

Authors:  Radwa R El-Tahan; Ahmed M Ghoneim; Hosam Zaghloul
Journal:  J Adv Res       Date:  2018-01-09       Impact factor: 10.479

8.  Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain.

Authors:  Claudia Palladino; Ifeanyi Jude Ezeonwumelu; Irene Mate-Cano; Pedro Borrego; Paula Martínez-Román; Sonia Arca-Lafuente; Salvador Resino; Nuno Taveira; Verónica Briz
Journal:  Sci Rep       Date:  2020-08-03       Impact factor: 4.379

9.  Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.

Authors:  Lize Cuypers; Ana Belén Pérez; Natalia Chueca; Teresa Aldamiz-Echevarría; Juan Carlos Alados; Ana María Martínez-Sapiña; Dolores Merino; Juan Antonio Pineda; Francisco Téllez; Nuria Espinosa; Javier Salméron; Antonio Rivero-Juarez; María Jesús Vivancos; Víctor Hontañón; Anne-Mieke Vandamme; Féderico García
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

10.  What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis.

Authors:  Britt Skaathun; Annick Borquez; Antonio Rivero-Juarez; Sanjay R Mehta; Francisco Tellez; Manuel Castaño-Carracedo; Dolores Merino; Rosario Palacios; Juan Macías; Antonio Rivero; Natasha K Martin
Journal:  BMC Infect Dis       Date:  2020-08-08       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.